drugset / Trial / NCT01492582

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

NCT01492582

NaSingle-groupOpen-labelPrevention

Summary

This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2) determining the immune response to and safety/tolerability of the quadrivalent and nonavalent HPV vaccine in young cancer survivors.

Timeline

Start
2012-07
Primary completion
2019-02-08
Completion
2020-07-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil Vaccine Intramuscular
Subject Gardasil 9 Vaccine Intramuscular

Indications

No indication recorded.